Lantern Pharma Inc. Proceeds from Sale and Maturity of Marketable Securities
Lantern Pharma Inc. (LTRN) reported Proceeds from Sale and Maturity of Marketable Securities of $4.94 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2026-08-14
- Lantern Pharma Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2026-06-30 was $692.25K, a 90.18% decline year-over-year.
- Lantern Pharma Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2026-03-31 was $4.25M, a 48.32% decline year-over-year.
- Lantern Pharma Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2025-12-31 was $2.50M, a 23.04% decline year-over-year.
- Lantern Pharma Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2025-09-30 was $8.01M, a 110.68% increase year-over-year.
- Lantern Pharma Inc. proceeds from sale and maturity of marketable securities for fiscal 2025 was $25.78M, a 24.80% increase from fiscal 2024.
- Lantern Pharma Inc. proceeds from sale and maturity of marketable securities for fiscal 2024 was $20.66M, a 183.58% increase from fiscal 2023.
- Lantern Pharma Inc. proceeds from sale and maturity of marketable securities for fiscal 2023 was $7.28M, a 76.83% increase from fiscal 2022.
- Lantern Pharma Inc. proceeds from sale and maturity of marketable securities for fiscal 2022 was $4.12M, a 6327.66% increase from fiscal 2021.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $692.25K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $4.94M 10-Q · filed 2026-08-14 | $7.44M derived: sum of 3 quarters · filed 2026-08-14 | $15.45M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $4.25M 10-Q · filed 2026-05-15 | $6.75M derived: sum of 2 quarters · filed 2026-05-15 | $14.76M derived: sum of 3 quarters · filed 2026-05-15 | $21.81M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $2.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $10.51M derived: sum of 2 quarters · filed 2026-03-30 | $17.56M derived: sum of 3 quarters · filed 2026-08-14 | $25.78M 10-K · filed 2026-03-30 |
| 2025-09-30 | $8.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $15.06M derived: sum of 2 quarters · filed 2026-08-14 | $23.28M 10-Q · filed 2025-11-12 | $26.53M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $7.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $15.27M 10-Q · filed 2026-08-14 | $18.52M derived: sum of 3 quarters · filed 2026-08-14 | $22.32M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $8.22M 10-Q · filed 2026-05-15 | $11.47M derived: sum of 2 quarters · filed 2026-05-15 | $15.27M derived: sum of 3 quarters · filed 2026-05-15 | $23.42M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $3.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $7.05M derived: sum of 2 quarters · filed 2026-03-30 | $15.20M derived: sum of 3 quarters · filed 2026-03-30 | $20.66M 10-K · filed 2026-03-30 |
| 2024-09-30 | $3.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $11.95M derived: sum of 2 quarters · filed 2025-11-12 | $17.41M 10-Q · filed 2025-11-12 | $19.23M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $8.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $13.61M 10-Q · filed 2025-08-13 | $15.43M derived: sum of 3 quarters · filed 2025-08-13 | $16.39M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $5.46M 10-Q · filed 2025-05-15 | $7.28M derived: sum of 2 quarters · filed 2025-05-15 | $8.24M derived: sum of 3 quarters · filed 2025-05-15 | $10.59M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $1.82M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $2.78M derived: sum of 2 quarters · filed 2025-03-27 | $5.13M derived: sum of 3 quarters · filed 2025-03-27 | $7.28M 10-K · filed 2025-03-27 |
| 2023-09-30 | $968.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $3.32M derived: sum of 2 quarters · filed 2024-11-07 | $5.47M 10-Q · filed 2024-11-07 | $6.67M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $2.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $4.50M 10-Q · filed 2024-08-08 | $5.70M derived: sum of 3 quarters · filed 2024-08-08 | $6.95M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $2.15M 10-Q · filed 2024-05-09 | $3.35M derived: sum of 2 quarters · filed 2024-05-09 | $4.60M derived: sum of 3 quarters · filed 2024-05-09 | $6.09M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $2.45M derived: sum of 2 quarters · filed 2024-03-18 | $3.94M derived: sum of 3 quarters · filed 2024-03-18 | $4.12M 10-K · filed 2024-03-18 |
| 2022-09-30 | $1.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $2.74M derived: sum of 2 quarters · filed 2023-11-08 | $2.92M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $1.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $1.67M 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | $176.52K 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $64.09K 10-K · filed 2023-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |